Mesoblast (MESO) Competitors $17.30 +0.63 (+3.78%) Closing price 04:00 PM EasternExtended Trading$17.39 +0.09 (+0.52%) As of 05:06 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends MESO vs. ROIV, RVMD, LNTH, BPMC, BBIO, LEGN, ELAN, CYTK, NUVL, and GRFSShould you be buying Mesoblast stock or one of its competitors? The main competitors of Mesoblast include Roivant Sciences (ROIV), Revolution Medicines (RVMD), Lantheus (LNTH), Blueprint Medicines (BPMC), BridgeBio Pharma (BBIO), Legend Biotech (LEGN), Elanco Animal Health (ELAN), Cytokinetics (CYTK), Nuvalent (NUVL), and Grifols (GRFS). These companies are all part of the "pharmaceutical products" industry. Mesoblast vs. Roivant Sciences Revolution Medicines Lantheus Blueprint Medicines BridgeBio Pharma Legend Biotech Elanco Animal Health Cytokinetics Nuvalent Grifols Roivant Sciences (NASDAQ:ROIV) and Mesoblast (NASDAQ:MESO) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, community ranking, dividends, valuation, institutional ownership, earnings, media sentiment, profitability and risk. Do institutionals & insiders believe in ROIV or MESO? 64.8% of Roivant Sciences shares are owned by institutional investors. Comparatively, 1.4% of Mesoblast shares are owned by institutional investors. 7.9% of Roivant Sciences shares are owned by company insiders. Comparatively, 18.8% of Mesoblast shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Which has more risk & volatility, ROIV or MESO? Roivant Sciences has a beta of 1.27, indicating that its share price is 27% more volatile than the S&P 500. Comparatively, Mesoblast has a beta of 3.36, indicating that its share price is 236% more volatile than the S&P 500. Do analysts rate ROIV or MESO? Roivant Sciences presently has a consensus price target of $17.93, suggesting a potential upside of 64.63%. Mesoblast has a consensus price target of $13.50, suggesting a potential downside of 19.02%. Given Roivant Sciences' stronger consensus rating and higher possible upside, equities analysts plainly believe Roivant Sciences is more favorable than Mesoblast.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Roivant Sciences 0 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.88Mesoblast 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75 Is ROIV or MESO more profitable? Roivant Sciences has a net margin of 3,827.42% compared to Mesoblast's net margin of 0.00%. Mesoblast's return on equity of 0.00% beat Roivant Sciences' return on equity.Company Net Margins Return on Equity Return on Assets Roivant Sciences3,827.42% -14.65% -13.19% Mesoblast N/A N/A N/A Does the media favor ROIV or MESO? In the previous week, Mesoblast had 5 more articles in the media than Roivant Sciences. MarketBeat recorded 12 mentions for Mesoblast and 7 mentions for Roivant Sciences. Roivant Sciences' average media sentiment score of 1.42 beat Mesoblast's score of 0.71 indicating that Roivant Sciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Roivant Sciences 3 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Mesoblast 5 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Does the MarketBeat Community believe in ROIV or MESO? Mesoblast received 359 more outperform votes than Roivant Sciences when rated by MarketBeat users. However, 77.27% of users gave Roivant Sciences an outperform vote while only 70.21% of users gave Mesoblast an outperform vote. CompanyUnderperformOutperformRoivant SciencesOutperform Votes5177.27% Underperform Votes1522.73% MesoblastOutperform Votes41070.21% Underperform Votes17429.79% Which has preferable valuation & earnings, ROIV or MESO? Roivant Sciences has higher revenue and earnings than Mesoblast. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRoivant Sciences$124.79M63.53$4.35B$5.651.93Mesoblast$5.90M324.02-$87.96MN/AN/A SummaryRoivant Sciences beats Mesoblast on 9 of the 16 factors compared between the two stocks. Get Mesoblast News Delivered to You Automatically Sign up to receive the latest news and ratings for MESO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MESO vs. The Competition Export to ExcelMetricMesoblastBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.97B$2.97B$5.24B$8.95BDividend YieldN/A1.94%5.13%4.04%P/E RatioN/A18.5059.1813.25Price / Sales324.02282.221,348.2177.80Price / CashN/A192.9043.7535.97Price / Book3.963.995.344.79Net Income-$87.96M-$41.02M$122.45M$224.76M7 Day Performance-2.97%6.06%0.30%1.14%1 Month Performance33.25%4.22%1.10%1.63%1 Year Performance858.05%4.75%26.86%20.32% Mesoblast Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MESOMesoblast0.8122 of 5 stars$17.30+3.8%$13.50-22.0%+810.9%$1.98B$5.90M0.0080Short Interest ↑ROIVRoivant Sciences3.6878 of 5 stars$10.70+0.7%$17.93+67.6%+0.3%$7.79B$129.13M1.89860Insider TradeOptions VolumePositive NewsRVMDRevolution Medicines4.5546 of 5 stars$42.46+1.6%$66.25+56.0%+45.7%$7.14B$742,000.00-11.83250News CoverageLNTHLantheus4.5456 of 5 stars$94.62-1.3%$131.86+39.4%+65.6%$6.58B$1.50B15.74700Analyst ForecastShort Interest ↑BPMCBlueprint Medicines1.6497 of 5 stars$100.53+15.0%$122.72+22.1%+29.1%$6.39B$434.42M-47.64640Analyst ForecastInsider TradeShort Interest ↑Analyst RevisionBBIOBridgeBio Pharma4.087 of 5 stars$33.16+14.0%$48.08+45.0%-9.2%$6.27B$217.77M-13.76400Short Interest ↑High Trading VolumeLEGNLegend Biotech2.4969 of 5 stars$31.80-5.4%$80.62+153.5%-47.9%$5.81B$520.18M-33.471,800Short Interest ↓ELANElanco Animal Health4.4149 of 5 stars$11.60+1.5%$16.43+41.6%-20.6%$5.73B$4.45B29.009,800CYTKCytokinetics4.3151 of 5 stars$46.49-0.3%$83.64+79.9%-42.1%$5.49B$7.53M-8.64250Analyst ForecastNUVLNuvalent1.8282 of 5 stars$70.72-7.7%$112.36+58.9%+2.4%$5.02BN/A-20.3840Analyst ForecastNews CoverageGRFSGrifols2.0414 of 5 stars$7.25-0.5%N/A-1.2%$4.98B$7.01B5.9426,300Positive NewsGap Down Related Companies and Tools Related Companies ROIV Competitors RVMD Competitors LNTH Competitors BPMC Competitors BBIO Competitors LEGN Competitors ELAN Competitors CYTK Competitors NUVL Competitors GRFS Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:MESO) was last updated on 1/17/2025 by MarketBeat.com Staff From Our PartnersI was wrong. Dead wrong. I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredStunning Trump Exec Order LeakedThis secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode in 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAll of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you k...Crypto Swap Profits | Sponsoredliberals FOOLED by Elon’s shocking surpriseElon Musk and Donald Trump fooled everyone. They said it was to “save free speech”... Or “fix what the l...StocksToTrade | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mesoblast Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Mesoblast With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
